Investigator-assessed best response among all enrolled patients in the 3-year analysis
| . | FL (n = 127) . | MZL (n = 31) . | All patients (N = 159)∗ . |
|---|---|---|---|
| ORR, n (%) | 119 (94) | 24 (77) | 143 (90) |
| CR | 100 (79) | 20 (65) | 120 (75) |
| PR | 19 (15) | 4 (13) | 23 (14) |
| SD, n (%) | 2 (2) | 3 (10) | 5 (3) |
| PD, n (%) | 2 (2) | 1 (3) | 3 (2) |
| Not done, n (%) | 4 (3) | 3 (10) | 8 (5) |
| DOR, median (95% CI), mo | 38.6 (29.0-NE) | NR (13.4-NE) | 38.6 (33.1-NE) |
| Estimate at 36 mo (95% CI), % | 57 (47-66) | 64 (40-80) | 58 (48-66) |
| Duration of CR, median (95% CI), mo | NR (35.4-NE) | NR (14.2-NE) | NR (35.4-NE) |
| Estimate at 36 mo (95% CI), % | 62 (48-72) | NR (NE-NE) | 61 (49-72) |
| Duration of PR, median (95% CI), mo | 4.9 (2.2-8.2) | 3.5 (1.9-NE) | 4.9 (2.1-6.2) |
| Estimate at 36 mo (95% CI), % | NR (NE-NE) | 0 (NE-NE) | NR (NE-NE) |
| . | FL (n = 127) . | MZL (n = 31) . | All patients (N = 159)∗ . |
|---|---|---|---|
| ORR, n (%) | 119 (94) | 24 (77) | 143 (90) |
| CR | 100 (79) | 20 (65) | 120 (75) |
| PR | 19 (15) | 4 (13) | 23 (14) |
| SD, n (%) | 2 (2) | 3 (10) | 5 (3) |
| PD, n (%) | 2 (2) | 1 (3) | 3 (2) |
| Not done, n (%) | 4 (3) | 3 (10) | 8 (5) |
| DOR, median (95% CI), mo | 38.6 (29.0-NE) | NR (13.4-NE) | 38.6 (33.1-NE) |
| Estimate at 36 mo (95% CI), % | 57 (47-66) | 64 (40-80) | 58 (48-66) |
| Duration of CR, median (95% CI), mo | NR (35.4-NE) | NR (14.2-NE) | NR (35.4-NE) |
| Estimate at 36 mo (95% CI), % | 62 (48-72) | NR (NE-NE) | 61 (49-72) |
| Duration of PR, median (95% CI), mo | 4.9 (2.2-8.2) | 3.5 (1.9-NE) | 4.9 (2.1-6.2) |
| Estimate at 36 mo (95% CI), % | NR (NE-NE) | 0 (NE-NE) | NR (NE-NE) |
DLBCL, diffuse large B-cell lymphoma; NE, not estimable; NR, not reached; PR, partial response; SD, stable disease.
One patient was found to have disease type DLBCL after enrollment via pretreatment biopsy. This patient did not receive axi-cel and discontinued the study.